For passive targeting of liposomes to tumor tissues, we earlier developed reticuloendothelial system (RES)-avoiding liposomes modified with a uronic acid derivative, palmityl-D-glucuronide (PGlcUA). In the present study, we encapsulated technetium-99m (99mTc)-diethylenetriaminepentaacetic acid (DTPA) in PGlcUA-liposomes (dipalmitoylphosphatidylcholine:cholesterol:PGlcUA = 40:40:20 as a molar ratio) and studied the biodistribution of the liposomes in tumor-bearing mice. 99mTc-DTPA encapsulated in liposomes effectively accumulated in tumor tissues after intravenous administration. Corresponding to these results, tumor was strongly imaged by a gamma-camera when 99mTc-DTPA-encapsulated PGlcUA-liposomes were used.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0969-8051(93)90071-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Conventional liposome performance and evaluation: lessons from the development of Vescan.
J Liposome Res
January 2008
Gilead Sciences Inc., San Dimas, California, USA.
In the early 1980s, Vestar Inc., a company founded on the basis of science developed by the California Institute of Technology and the City of Hope, brought into development an imaging agent based on liposome encapsulated (111)In(3+). This agent, named Vescan, together with the gamma ray perturbed angular correlation spectroscopy technique to examine liposome integrity, was envisioned as a broadly applicable in vivo tumor diagnostic agent.
View Article and Find Full Text PDFTheoretical considerations of RES-avoiding liposomes: Molecular mechanics and chemistry of liposome interactions.
Adv Drug Deliv Rev
June 1998
Department of Radiology, Division of Nuclear Medicine, Massachusetts General Hospital and Harvard Medical School, Radiology EDR-517, MGH, Boston, MA 02114, USA
The development of long-circulating, RES-avoiding liposomes has become a remarkable milestone in the progress of contemporary pharmacology. Drugs incorporated in such liposomes are protected from fast metabolization and clearance, and can be further targeted to a desired tissue site. Ideally, future developments should result in drug carriers which can identify and act upon their targets with even higher efficiency and selectivity, preferably close to or exceeding that of the natural immune cells.
View Article and Find Full Text PDF[Basic study and application of functional liposomes].
Yakugaku Zasshi
July 1995
School of Pharmaceutical Sciences, University of Shizuoka, Japan.
Liposomes are the models of biomembranes and are new thought to be ideal tools in the field of drug delivery system. Liposomalization of various drugs has been revealed to enhance their efficacy and to reduce the side effect of the drugs. For the site-specific delivery, intracellular targeting, and controlled release of drugs, many functional liposomes have been developed based on their natures as the models of biomembranes.
View Article and Find Full Text PDFTherapeutic effect of reticuloendothelial system (RES)-avoiding liposomes containing a phospholipid analogue of 5-fluorouracil, dipalmitoylphosphatidylfluorouridine, in Meth A sarcoma-bearing mice.
Biol Pharm Bull
October 1994
Department of Radiobiochemistry, School of Pharmaceutical Sciences, University of Shizuoka, Japan.
Reticuloendothelial system (RES)-avoiding liposomes are known to accumulate in tumor tissues due to passive targeting. Dipalmitoylphosphatidylfluorouridine (DPPF), a potent antitumor agent readily incorporated into the lipid bilayer, was embedded in RES-avoiding liposomes modified with a uronic acid derivative, palmityl-D-glucuronide (PGlcUA). The therapeutic effect of DPPF in PGlcUA-liposomes was examined in tumor-bearing mice.
View Article and Find Full Text PDFMembrane modification by negatively charged stearyl-polyoxyethylene derivatives for thermosensitive liposomes: reduced liposomal aggregation and avoidance of reticuloendothelial system uptake.
J Drug Target
February 1995
DDS Research Laboratories, Takeda Chemical Industries Ltd., Osaka, Japan.
In order to avoid reticuloendothelial system (RES) uptake and prolong systemic circulation of cisplatin (CDDP)-encapsulating thermosensitive liposomes, stearylpolyoxyethylene (POE) derivatives [SnC, stearyl-O-(CH2CH2O)n-CH2COONa] were incorporated as membrane modifiers into lipid bilayers composed of dipalmitoylphosphatidylcholine (DPPC) and distearoylphosphatidylcholine (DSPC). The incorporation of S2C, S5C, S10C or S15C [lipid/SnC = 10/2 (w/w)] greatly reduced liposomal aggregation without impairing liposomal stability. After being intravenously administered to rats, the liposomes remained longer in the systemic circulation and showed lower RES levels than the control liposomes.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!